Aurobindo Pharma Limited
AUROPHARMA
Rank in Stocks
#2068
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Share Price
$17.34
Market Cap
$9.98B
Change (1 day)
-3.08%
Change (1 year)
38.71%
Country
IN
Trade Aurobindo Pharma Limited (AUROPHARMA)
Category
Healthcare
Earnings for Aurobindo Pharma Limited (AUROPHARMA)
Earnings in Jun 2026 TTM: $598.16M
According to Aurobindo Pharma Limited latest financial reports the company's current earnings are $598.16M. In 2024 the company made an earning of $525.28M, an increase over its 2023 earnings that were of $317.90M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Aurobindo Pharma Limited from 2004 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $598.16M | 0.98% |
| 2025 | $592.37M | 12.77% |
| 2024 | $525.28M | 65.24% |
| 2023 | $317.90M | -28.45% |
| 2022 | $444.31M | -55.71% |
| 2021 | $1.00B | 101.91% |
| 2020 | $496.85M | 11.61% |
| 2019 | $445.18M | -10.57% |
| 2018 | $497.80M | 5.47% |
| 2017 | $471.99M | 13.94% |
| 2016 | $414.23M | 19.23% |
| 2015 | $347.42M | -3.94% |
| 2014 | $361.67M | 425.28% |
| 2013 | $68.85M | -263.95% |
| 2012 | $-42.00M | -123.75% |
| 2011 | $176.86M | 5.59% |
| 2010 | $167.49M | 1,070.92% |
| 2009 | $14.30M | -80.38% |
| 2008 | $72.91M | 53.10% |
| 2007 | $47.62M | 115.32% |
| 2006 | $22.12M | 427.99% |
| 2005 | $4.19M | -88.08% |
| 2004 | $35.14M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 195.00% |
IN
|
